OPKO Health (NASDAQ:OPK) Stock Crosses Above 50 Day Moving Average of $1.09

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.09 and traded as high as $1.26. OPKO Health shares last traded at $1.26, with a volume of 1,947,276 shares trading hands.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on OPK shares. Barrington Research reiterated an "outperform" rating and set a $1.50 target price on shares of OPKO Health in a research note on Monday, April 1st. Piper Sandler reissued an "overweight" rating and set a $5.00 price target on shares of OPKO Health in a research report on Monday, April 1st. HC Wainwright reissued a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday, April 3rd. Finally, StockNews.com downgraded OPKO Health from a "hold" rating to a "sell" rating in a research report on Friday, March 1st.

OPKO Health Stock Performance

The firm has a market capitalization of $878.21 million, a P/E ratio of -5.04 and a beta of 1.82. The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average of $1.10 and a 200-day moving average of $1.23.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The firm had revenue of $181.90 million during the quarter, compared to analyst estimates of $177.53 million. During the same period last year, the company posted ($0.11) EPS. The business's quarterly revenue was down 1.9% on a year-over-year basis. On average, equities analysts anticipate that OPKO Health, Inc. will post -0.33 earnings per share for the current fiscal year.

Insider Activity at OPKO Health

In other news, Director Richard M. Krasno bought 30,000 shares of the firm's stock in a transaction that occurred on Monday, January 29th. The stock was acquired at an average cost of $0.99 per share, with a total value of $29,700.00. Following the transaction, the director now directly owns 103,333 shares of the company's stock, valued at approximately $102,299.67. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Richard M. Krasno purchased 30,000 shares of the business's stock in a transaction on Monday, January 29th. The stock was acquired at an average price of $0.99 per share, for a total transaction of $29,700.00. Following the purchase, the director now owns 103,333 shares of the company's stock, valued at $102,299.67. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Phillip Md Et Al Frost purchased 1,000,000 shares of the business's stock in a transaction on Wednesday, February 21st. The shares were bought at an average price of $0.99 per share, with a total value of $990,000.00. Following the purchase, the chief executive officer now directly owns 208,368,225 shares in the company, valued at approximately $206,284,542.75. The disclosure for this purchase can be found here. Insiders bought 4,630,000 shares of company stock valued at $4,422,700 in the last three months. Corporate insiders own 47.26% of the company's stock.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds and other institutional investors have recently modified their holdings of the business. IPG Investment Advisors LLC bought a new stake in shares of OPKO Health in the 4th quarter worth approximately $30,000. River Wealth Advisors LLC bought a new stake in shares of OPKO Health in the 3rd quarter worth approximately $38,000. SlateStone Wealth LLC bought a new stake in shares of OPKO Health in the 1st quarter worth approximately $31,000. Northstar Group Inc. bought a new stake in shares of OPKO Health in the 4th quarter worth approximately $42,000. Finally, EP Wealth Advisors LLC raised its holdings in shares of OPKO Health by 140.3% in the 3rd quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 18,041 shares during the period. Hedge funds and other institutional investors own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.